H-89 (dihydrochloride)


CAS No. : 130964-39-5

130964-39-5
Price and Availability of CAS No. : 130964-39-5
Size Price Stock
5mg $43 In-stock
10mg $67 In-stock
25mg $150 In-stock
50mg $259 In-stock
100mg $440 In-stock
200 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-15979A
M.Wt: 519.28
Formula: C20H22BrCl2N3O2S
Purity: >98 %
Solubility: H2O : 5 mg/mL (ultrasonic;warming;heat to 80°C);DMSO : 100 mg/mL (ultrasonic)
Introduction of 130964-39-5 :

H-89 dihydrochloride is a potent and selective inhibitor of protein kinase A (PKA) with an IC50 of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase. IC50 & Target: IC50: 48 nM (protein kinase A) In Vitro: H-89 inhibits protein kinase A, in competitive fashion against ATP. H-89 causes a dose-dependent inhibition of the forskolin-induced protein phosphorylation, with no decrease in intracellular cyclic AMP levels in PC12D cells. H-89 significantly inhibits the forskolin-induced neurite outgrowth from PC12D cells. H-89 (30 μM) inhibits significantly cAMP-dependent histone IIb phosphorylation activity in PC12D cell lysates[1]. H-89 (1-2 μM) significantly slows the repriming rate in rat skinned fibres, most likely due to it deleteriously affecting the T-system potential. H-89 (10-100 μM) inhibits net Ca2+ uptake by the SR and affectes the Ca2+-sensitivity of the contractile apparatus in rat skinned fibres[2]. In Vivo: H-89 (0.2 mg/100g, i.p.) significantly increases seizure latency and threshold in PTZ-treated animals. H-89 (0.05, 0.2 mg/100 g, i.p.) prevents the epileptogenic activity of bucladesine (300 nM) with significant increase of seizure latency and seizure threshold[3].

Your information is safe with us.